Image
Cover illustration;Tetralogy of Fallot, one of three congenital heart defects included in the study. Drawn by: Boris Nilsson, senior cardiac surgeon, pediatric heart center, Queen Silvia's Children's Hospital
Cover illustration;Tetralogy of Fallot , one of three congenital heart defects included in the study. Drawn by: Boris Nilsson, senior cardiac surgeon, pediatric heart center, Queen Silvia's Children's Hospital
Breadcrumb

Elin Thorlacius - Levosimendan vs. Milrinone: Early Renal and Hemodynamic Outcomes after lnfant Cardiac Surgery

Published

On November 16, Elin Thorlacius, is defended her thesis for Doctor of Medical Science at the Institute of Clinical Sciences, Sahlgrenska Academy, in the research subject of Anesthesiology and Intensive Care

The title of the thesis is: Levosimendan vs. Milrinone: Early Renal and Hemodynamic Outcomes after lnfant Cardiac Surgery

Link directly to the doctoral thesis

Image
Elin Thorlacius, överläkare i barnanestesi och barnintensivvård på Drottning Silvias barnsjukhus i Göteborg
Elin Thorlacius, consultant in pediatric anesthesia and pediatric intensive care at Queen Silvia's Children's Hospital in Gothenburg
Photo: Johan Magnusson

The thesis is about heart and kidney protection after heart surgery in infants and has been done in collaboration with the Children's Heart Center at Helsinki University Hospital.

Abstract

Background:
Myocardial and renal dysfunctions are common after cardiac surgery in young children, which increases risk of complications and delayed recovery. Inodilators, such as milrinone and levosimendan, are frequently used to reduce the risk of low cardiac output syndrome in infants after cardiac surgery. Levosimendan has been demonstrated to increase renal blood flow and glomerular filtration rate in adult
cardiac surgery, however there is a lack of infant studies. In the present thesis, the ability of levosimendan compared to milrinone in reducing renal and myocardial injuries after cardiac surgery in infants was investigated.

Methods:
Two Nordic pediatric heart centers, Gothenburg and Helsinki, performed a double-blinded, randomized clinical trial (MiLe-1). Seventy infants, scheduled for total corrective cardiac surgery with cardiopulmonary bypass (CPB), received either levosimendan or milrinone. We performed the following comparisons between the
two study groups: 1) the incidence of postoperative acute kidney injury (AKI), 2) the myocardial function with echocardiography, 3) changes in the plasma concentrations of myocardial biomarkers over time, and 4) in the whole study population, the associations between biomarkers of inflammation, renal, and myocardial dysfunction, with early clinical outcomes after cardiac surgery.

Results:
The postoperative incidence of AKI was 39.5% in the milrinone group and 46.9% in the levosimendan group. The difference was not statistically significant. Neither was there a significant difference between the study groups regarding hemodynamic parameters, echocardiographic measurements, or the cardiac biomarkers. The peak plasma concentrations of the cardiac injury and inflammatory biomarkers were strong predictors of the development of severe AKI. In the patients with the lowest and highest quartile of the cardiac injury biomarker hs-cTnT and the proinflammatory biomarker IL-8 (measured at 2 hours post-CPB), we observed a strong association with the postoperative duration of ventilatory support, and the need of vasopressors.

Conclusion:
We could not detect any significant differences in the incidence of AKI, myocardial function, or in the myocardial biomarkers after cardiac surgery in infants who received either levosimendan or milrinone. Plasma hs-cTnT and IL-8, measured 2 hours post-CPB, may have clinical value in infants after cardiac surgery, including
early weaning of ventilatory support.

Ett flödesdiagram från ramen i avhandlingen.
The primary aim of the MiLe-1 trial was to compare the levels of plasma creatinine, as a marker of AKI, in patients who received levosimendan versus those who received milrinone. Fig 17, page 28 from thesis.
Photo: Elin Thorlacius
MORE INFORMATION ABOUT THE DISSERTATION

Time: 221116 kl 13.00 Place: Föreläsningssalen Tallen, Drottning Silvias barn- och ungdomssjukhus, Behandlingsvägen 7, Göteborg

OBS: The dissertation can also be followed via the link below: (coming soon)

Supervisor: Albert Castellheim
Co-Supervisor: Sven-Erik Ricksten and Håkan Wåhlander
Opponent: Urban Fläring, Karolinska institutet, Stockholm
Examining Committee: Åsa Torinsson Naluai, Lars Mikael Broman and Linda Block